Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Model After Continuing or Switching to a Doravirine-Based HIV Treatment Regimen
Related Posts
Nayak TK, Bajpai A, Patwa V, Carter RL, Enjamuri N, Gao E, Rajan S, Xiang YK, Tilley DG. Myeloid cell-specific β2-adrenergic receptor deletion improves early[...]
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima A, Serruys PW, Garg S, McEvoy JW, Wood DA, Doenst T, Taggart DP, Puskas JD, Shajahan A, Sharif F, Miyashita K, Tobe A, Tsai[...]
Nikitas J, Smith CP, Armstrong WR, Murthy V, Grogan T, Clark K, Moore J, Roberts M, Farolfi A, Reiter RE, Rettig MB, Shen J, Valle[...]